Endophenotyping Oxaliplatin Hypersensitivity: Personalizing Desensitization to the Atypical Platin

Silver, Jared; Garcia-Neuer, Marlene; Lynch, Donna‐Marie; Paşaoğlu, Gülden; Sloane, David E. E.; Castells, M.

doi:10.1016/j.jaip.2020.02.013

Cited by 39 publications

(77 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the incidence of oxaliplatin reactions range from 7.1% in the first six cycles to 20.6% when patients receive more than six cycles, with the majority reacting during the 7 th to 9 th infusion [27]. However, patients who develop CRR with oxaliplatin usually react during the first exposures [13]. Similar findings are obtained with cisplatin whose incidence varies from 5% to 20% [28].…”

Section: Hypersensitivity To Cancer Chemotherapymentioning

confidence: 56%

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

Vega¹,

Jiménez-Rodriguez²,

Barranco³

et al. 2021

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

Section: Hypersensitivity To Cancer Chemotherapymentioning

confidence: 56%

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

Vega¹,

Jiménez-Rodriguez²,

Barranco³

et al. 2021

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

show abstract

“…Some resemble type 1 reactions and respond to desensitization, as in this case. Others are atypical, possibly mast cellindependent cytokine release reactions refractory to desensitization [15].…”

Section: Discussionmentioning

confidence: 99%

A case report of an adverse drug reaction with a combination of oxaliplatin and perindopril

Okello¹

2022

J Case Rep Images Oncology

View full text Add to dashboard Cite

Introduction:Oxaliplatin is a third-generation platinum compound that is used as a single agent and in combination with fluorouracil (5-FU) to treat a variety of solid organ cancers. Patients treated with Oxaliplatin may develop hypersensitivity reactions. Angiotensinconverting enzyme inhibitors (ACEI) are established to have multiple cardiovascular benefits. Recent studies also suggest that ACEI may have a role in preventing Oxaliplatin-induced peripheral neuropathy. Case Report:We present a case of a patient who presented with adverse reactions on two separate occasions. At the time of the first reaction he had been on an ACEI (Perindopril), which he had used for four years for management of hypertension and was within hours of receiving the seventh cycle of adjuvant modified Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX-6) for ypT3N0 rectal adenocarcinoma. On the second episode, he presented with a reaction before his eighth cycle of chemotherapy, while still taking the ACEI. Determination of the cause of the reactions was challenging and management involved switching from Perindopril to a calcium channel blocker (Amlodipine) and Oxaliplatin desensitization. The patient was able to complete chemotherapy treatment with no further reactions. Conclusion:The combination of Perindopril with Oxaliplatin could increase the risk of adverse reactions. These adverse reactions could be managed by substituting Perindopril with a calcium channel blocker and use of an Oxaliplatin desensitization protocol.

show abstract

“…Then, they started treatment with antihistamine every 24 hours 3 days before the cycle, and she did not have any reaction since the 11th desensitization until complete 20 cycles. [51][52][53][54] In 2018, Isabwe et al 55 analyzed 524 mab desensitizations in 104 patients between 2014 and 2016 presenting 3 desensitizations to CPIs. One patient with an initial grade I reaction to nivolumab experienced 2 drug desensitizations.…”

Section: Drug Desensitization To Checkpoint Inhibitors In Real Lifementioning

confidence: 99%

Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor–monoclonal antibodies and desensitization

Labella

Castells

2021

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

To review type 1 hypersensitivity reactions and anaphylaxis to checkpoint inhibitor−monoclonal antibodies and its management with drug desensitization. Data Sources: English-language literature on MEDLINE regarding hypersensitivity, anaphylaxis, and checkpoint inhibitor−monoclonal antibodies. Study Selections: References were selected based on relevance, novelty, robustness, and applicability. Results: There are well-known tissue toxicities associated to checkpoint inhibitors, but hypersensitivity reactions and anaphylaxis have been underreported. The presentation of these reactions is based on clinical phenotypes with underlying endotypes identified by specific biomarkers. Drug desensitizations have been successfully applied to checkpoint inhibitor drugs to allow patients with cancer to receive first-line therapies. This review provides current best practices for the recognition and diagnosis of hypersensitivity reactions and anaphylaxis to checkpoint inhibitors and their management using drug desensitization. Conclusion: Hypersensitivity reactions and anaphylaxis have been identified as potential adverse effects induced by checkpoint inhibitor−monoclonal antibodies. Drug desensitization is a safe and effective treatment option for patients who experience hypersensitivity reactions in need of these monoclonal antibodies to improve cancer outcomes.

show abstract

Endophenotyping Oxaliplatin Hypersensitivity: Personalizing Desensitization to the Atypical Platin

Cited by 39 publications

References 41 publications

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

Hypersensitivity Reactions to Cancer Chemotherapy: Practical Recommendations of ARADyAL for Diagnosis and Desensitization

A case report of an adverse drug reaction with a combination of oxaliplatin and perindopril

Hypersensitivity reactions and anaphylaxis to checkpoint inhibitor–monoclonal antibodies and desensitization

Contact Info

Product

Resources

About